As Novo Nordisk transitions from the leadership of longtime CEO Lars Fruergaard Jørgensen to newly appointed chief Maziar ...

Danish drugmaker Novo Nordisk (NVO) has implemented a hiring freeze, which will apply across all markets and departments, ...

Novo Nordisk, the Denmark-based pharmaceutical company that makes Ozempic and Wegovy, looks like it's being toppled off its ...

Maziar Mike Doustdar takes office as NVO's new CEO, bringing a proven global growth record to tackle rising obesity market ...

Lars Fruergaard Jørgensen says: “Serving as Novo Nordisk’s CEO for the past eight years has been a privilege and an experience that I will always cherish.

After an unusual first quarter in which seven of the biopharma industry’s | Several U.S. pharma companies that had posted ...

CEO Lars Fruergaard Jørgensen said that efforts to bolster supply of the wildly popular weight-loss drug had resulted in the drug's removal from a drug shortage list. "Given the significant ...

Novo Nordisk has a commercial relationship with Economist Impact, a division of The Economist Group. The Economist operates ...

Lars Rebien Sørensen has pharmaceutical industry expertise from his 16-year tenure as CEO. In the pre-market trading, 5.37% lesser at $62.60 on the New York Stock Exchange.

Lars Fruergaard Jørgensen Good. Thank you, Truong. First, Karsten, on NovoSeven growth. Karsten Munk Knudsen Yes. So we've been looking at our -- at NovoSeven for quite a number of years now.

CEO Lars Fruergaard Jørgensen told shareholders at its Annual General Meeting that it was pursuing legal action against companies it believes to be violating its intellectual property.

Lars Fruergaard Jørgensen Thank you, Simon. So on Ozempic device looking at the current performance of Ozempic I think we have concluded that we have a very, very strong device supporting the drug.